Japan To Reimburse Zolgensma – But At Lower Price Than US
NHI Scheme Grants Coverage
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.
You may also be interested in...
The Swiss major is offering a ‘Day One’ access program to governments and reimbursement agencies for Zolgensma, which is already available in France and will be shortly in Germany.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.